Medline to Buy Back $200 Million of Stock From Private Equity Backers Alongside 60 Million-Share Secondary Offering
Medline agreed to buy back $200 million of its stock directly from its private equity backers as they sell 60 million shares in a secondary offering, the medical supplies company said in an 8-K filed Wednesday.
The offering was priced at $35.50 a share on Nov. 17, according to a press release filed with the 8-K. The sellers are entities affiliated with Blackstone, The Carlyle Group and Hellman & Friedman, along with GIC and a wholly owned subsidiary of the Abu Dhabi Investment Authority.
Medline is not selling any shares and will not receive proceeds from the offering. The sale is expected to bring the selling stockholders net proceeds of an estimated $2.1 billion, the company said, before any exercise of the underwriters' 30-day option to buy up to 9,000,000 more shares.
The buyback
Under a repurchase agreement signed Nov. 16, Medline and Medline Holdings will buy $200 million of Class A common stock and Medline Holdings partnership units from the same sellers, at the price per interest the underwriters pay in the offering, according to the filing.
When units are repurchased, the seller will also hand over an equal number of Class B shares, which will be canceled, the filing says.
The repurchase was approved by the audit committee of Medline's board, which consists solely of independent directors. It counts toward the company's previously announced share repurchase program.
The repurchase is set to close at the same time as the offering and depends on the offering closing. The offering is expected to close on Nov. 23, subject to customary conditions.
By the numbers
- Secondary offering: 60,000,000 shares at $35.50
- Underwriters' option: up to 9,000,000 more shares
- Company repurchase: $200 million
- Expected closing: Nov. 23, 2026
Sources
- Form 8-K (Items 1.01 and 8.01, Exhibit 99.1), Medline Inc., share and unit repurchase agreement and secondary offering pricing, filed Nov. 18, 2026, accession 0001193125-26-467193
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.